Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 12% Improvement Relative Risk Mortality 17% Mortality, day 15 21% Ventilation 47% Recovery 9% Hospitalization time -11% Remdesivir  CATCO  LATE TREATMENT  RCT Is late treatment with remdesivir beneficial for COVID-19? RCT 1,281 patients in Canada Lower ventilation (p=0.00028) and longer hospitalization (p=0.036) c19early.org Ali et al., Canadian Medical Associati.., Jan 2022 Favors remdesivir Favors control

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Ali et al., Canadian Medical Association Journal, doi:10.1503/cmaj.211698, CATCO, NCT04330690
Jan 2022  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 1,282 hospitalized patients in Canada showing lower mechanical ventilation with remdesivir treatment, but no significant difference for mortality.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 12.0% lower, RR 0.88, p = 0.21, treatment 127 of 634 (20.0%), control 152 of 647 (23.5%), NNT 29, day 60.
risk of death, 17.0% lower, RR 0.83, p = 0.09, treatment 117 of 634 (18.5%), control 145 of 647 (22.4%), NNT 25, in hospital.
risk of death, 20.6% lower, RR 0.79, p = 0.59, treatment 14 of 634 (2.2%), control 18 of 647 (2.8%), NNT 174, day 15.
risk of mechanical ventilation, 47.0% lower, RR 0.53, p < 0.001, treatment 46 of 634 (7.3%), control 89 of 647 (13.8%), NNT 15, day 60.
risk of no recovery, 9.0% lower, RR 0.91, p = 0.41, treatment 634, control 647, clinical status, day 60.
hospitalization time, 11.1% higher, relative time 1.11, p = 0.04, treatment median 10.0 IQR 12.0 n=634, control median 9.0 IQR 11.0 n=647.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ali et al., 19 Jan 2022, Randomized Controlled Trial, Canada, peer-reviewed, 85 authors, average treatment delay 8.0 days, trial NCT04330690 (history) (CATCO).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
Karim Ali, Tanweer Azher, Mahin Baqi, Alexandra Binnie, Sergio Borgia, François M Carrier, Yiorgos Alexandroa Cavayas, Nicolas Chagnon, Matthew P Cheng, John Conly, Cecilia Costiniuk, Peter Daley, Nick Daneman, Josh Douglas, Catarina Downey, Erick Duan, Emmanuelle Duceppe, Madeleine Durand, Shane English, George Farjou, Evradiki Fera, Patricia Fontela, Rob Fowler, Michael Fralick, Anna Geagea, Jennifer Grant, Luke B Harrison, Thomas Havey, Holly Hoang, Lauren E Kelly, Yoav Keynan, Kosar Khwaja, Gail Klein, Marina Klein, Christophe Kolan, Nadine Kronfli, Francois Lamontagne, Rob Lau, Michael Fralick, Todd C Lee, Nelson Lee, Rachel Lim, Sarah Longo, Alexandra Lostun, Erika Macintyre, Isabelle Malhamé, Kathryn Mangof, Marlee Mcguinty, Sonya Mergler, Matthew P Munan, Srinivas Murthy, Conar O’neil, Daniel Ovakim, Jesse Papenburg, Ken Parhar, Seema Nair Parvathy, Chandni Patel, Santiago Perez-Patrigeon, Ruxandra Pinto, Subitha Rajakumaran, Asgar Rishu, Malaika Roba-Oshin, Moira Rushton, Mariam Saleem, Marina Salvadori, Kim Scherr, Kevin Schwartz, Makeda Semret, Michael Silverman, Ameeta Singh, Wendy Sligl, Stephanie Smith, Ranjani Somayaji, Darrell H S Tan, Siobhan Tobin, Meaghan Todd, Tuong-Vi Tran, Alain Tremblay, Jennifer Tsang, Alexis Turgeon, Erik Vakil, Jason Weatherald, Cedric Yansouni, Ryan Zarychanski
Canadian Medical Association Journal, doi:10.1503/cmaj.211698
T he role of remdesivir in treating patients in hospital with COVID-19 remains ill defined. 1 Remdesivir, a repurposed antiviral medication, has full or emergency approval from a number of regulators -including Health Canada -for the treatment of COVID-19, based on clinical trial data documenting a benefit on improving time to recovery. 2 An interim report of the larger World Health Organization (WHO) Solidarity trial showed no difference regarding mortality or need for mechanical ventilation, with a number of smaller trials being inconclusive on these important outcomes. [3] [4] [5] [6] Recommendations of clinical guidelines are mixed, with some recommending remdesivir as standard of care, and others weakly recommending against. 7, 8 Its impact on other clinical outcomes, including resource utilization and post-hospital stay outcomes, has not been fully defined, and there remains a possibility of an important treatment effect, particularly in certain groups of patients. 9 Research Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial Canadian Treatments for COVID-19 (CATCO)*; for the Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group
Authors: Karim Ali, Tanweer Azher, Mahin Baqi, Alexandra Binnie, Competing interests: Alexandra Binnie reports receiving research grants from the Canadian Institutes of Health Research (CIHR) and the Physicians Services Incorporated Foundation. Sergio Borgia reports receiving honoraria from Gilead Sciences and GSK. Yiorgos Alexandros Cavayas reports receiving a grant from CIHR. Matthew Cheng reports receiving grants from the McGill Interdisciplinary Initiative in Infection and Immunity and from CIHR, during the conduct of the study (payments made to the institution). Dr. Cheng also reports receiving personal fees from AstraZeneca, outside the submitted work; and from Nplex Biosciences and GEn1E lifesciences (in the form of stock options for being a member of the scientific advisory board) outside the submitted work. Dr. Cheng co-founded Kanvas Biosicences and owns equity in the company, and reports 3 patents pending. Ameeta Singh reports receiving consulting fees from Gilead for membership of an advisory board. Ranjani Somayaji reports receiving contract research funding from Sunnybrook Research Institute, University of Calgary and Calgary Health Foundation, and clinical research funding from CIHR and the Cystic Fibrosis Foundation. Dr. Somayaji also reports participation on an oncovir data monitoring safety board. Darrell Tan reports receiving grants from AbbVie (in-kind drug only) and Gilead (inkind drug and grants to institution), and a contract between GSK and the..
References
Ader, Bouscambert-Duchamp, Hites, Discovery Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial, Lancet Infect Dis, doi:10.1016/S1473-3099(21)00485-0
Adhikari, Fowler, Bhagwanjee, Critical care and the global burden of critical illness in adults, Lancet
Agarwal, Rochwerg, Siemieniuk, A living WHO guideline on drugs for COVID-19, BMJ
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19: final report, N Engl J Med
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19: preliminary report. Reply, N Engl J Med
Bhimraj, Morgan, Shumaker, IDSA guidelines on the treatment and management of patients with COVID-19
Borgia, Carrier, Cavayas, Chagnon, Cheng et al., Departments of Anesthesiology (Carrier), Medicine (Duceppe, Kolan), Intensive Care Medicine (Carrier) and Internal Medicine (Duceppe, Kolan) and Internal Medicine Service
Donnelly, Wang, Iwashyna, Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system, JAMA
Estcourt, Turgeon, Mcquilten, Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial, JAMA
Ford, Pragmatic trials, N Engl J Med
French, Hulse, Nguyen, Impact of hospital strain on excess deaths during the COVID-19 pandemic: United States, July 2020-July 2021, MMWR Morb Mortal Wkly Rep
Goldman, Lye, Hui, Remdesivir for 5 or 10 days in patients with severe COVID-19, N Engl J Med
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med
Lee, Lee, Kim, TMPRSS2 and RNA-dependent RNA polymerase are effective targets of therapeutic intervention for treatment of COVID-19 caused by SARS-CoV-2 variants (B.1.1.7 and B.1.351, Microbiol Spectr
Lee, Mcdonald, Butler-Laporte, Remdesivir and systemic corticosteroids for the treatment of COVID-19: a Bayesian re-analysis, Int J Infect Dis
Mahajan, Singh, Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study, Indian J Anaesth
Murthy, Archambault, Atique, SPRINT-SARI Canada Investigators and the Canadian Critical Care Trials Group. Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study, CMAJ Open
Naylor, Boozary, Adams, Canadian federal-provincial/territorial funding of universal health care: fraught history, uncertain future, CMAJ
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results, N Engl J Med
Rochwerg, Agarwal, Zeng, Remdesivir for severe COVID-19: a clinical practice guideline, BMJ
Spinner, Gottlieb, Criner, GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Verma, Hora, Jung, Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area, CMAJ
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Wunsch, Angus, Harrison, Variation in critical care services across North America and Western Europe, Crit Care Med
Yehya, Harhay, Curley, Reappraisal of ventilator-free days in critical care research, Am J Respir Crit Care Med
Yusuf, Wittes, Interpreting geographic variations in results of randomized, controlled trials, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit